These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
217 related articles for article (PubMed ID: 23814052)
21. The p38 mitogen-activated protein kinase pathway and its role in interferon signaling. Platanias LC Pharmacol Ther; 2003 May; 98(2):129-42. PubMed ID: 12725866 [TBL] [Abstract][Full Text] [Related]
22. Emodin potentiates the antiproliferative effect of interferon α/β by activation of JAK/STAT pathway signaling through inhibition of the 26S proteasome. He Y; Huang J; Wang P; Shen X; Li S; Yang L; Liu W; Suksamrarn A; Zhang G; Wang F Oncotarget; 2016 Jan; 7(4):4664-79. PubMed ID: 26683360 [TBL] [Abstract][Full Text] [Related]
24. Interferons activate the p42/44 mitogen-activated protein kinase and JAK-STAT (Janus kinase-signal transducer and activator transcription factor) signalling pathways in hepatocytes: differential regulation by acute ethanol via a protein kinase C-dependent mechanism. Nguyen VA; Chen J; Hong F; Ishac EJ; Gao B Biochem J; 2000 Jul; 349(Pt 2):427-34. PubMed ID: 10880341 [TBL] [Abstract][Full Text] [Related]
25. Inhibiting ERK/Mnk/eIF4E broadly sensitizes ovarian cancer response to chemotherapy. Liu S; Zha J; Lei M Clin Transl Oncol; 2018 Mar; 20(3):374-381. PubMed ID: 28766096 [TBL] [Abstract][Full Text] [Related]
26. TSC patient-derived isogenic neural progenitor cells reveal altered early neurodevelopmental phenotypes and rapamycin-induced MNK-eIF4E signaling. Martin P; Wagh V; Reis SA; Erdin S; Beauchamp RL; Shaikh G; Talkowski M; Thiele E; Sheridan SD; Haggarty SJ; Ramesh V Mol Autism; 2020; 11(1):2. PubMed ID: 31921404 [TBL] [Abstract][Full Text] [Related]
27. Induction of TRIM22 by IFN-γ Involves JAK and PC-PLC/PKC, but Not MAPKs and pI3K/Akt/mTOR Pathways. Gao B; Xu W; Wang Y; Zhong L; Xiong S J Interferon Cytokine Res; 2013 Oct; 33(10):578-87. PubMed ID: 23659673 [TBL] [Abstract][Full Text] [Related]
28. Interferon-alpha2b reduces phosphorylation and activity of MEK and ERK through a Ras/Raf-independent mechanism. Romerio F; Riva A; Zella D Br J Cancer; 2000 Aug; 83(4):532-8. PubMed ID: 10945503 [TBL] [Abstract][Full Text] [Related]
29. The IRS-pathway operates distinctively from the Stat-pathway in hematopoietic cells and transduces common and distinct signals during engagement of the insulin or interferon-alpha receptors. Uddin S; Fish EN; Sher D; Gardziola C; Colamonici OR; Kellum M; Pitha PM; White MF; Platanias LC Blood; 1997 Oct; 90(7):2574-82. PubMed ID: 9326223 [TBL] [Abstract][Full Text] [Related]
30. Activation of mitogen-activated protein kinase kinase (MKK) 3 and MKK6 by type I interferons. Li Y; Batra S; Sassano A; Majchrzak B; Levy DE; Gaestel M; Fish EN; Davis RJ; Platanias LC J Biol Chem; 2005 Mar; 280(11):10001-10. PubMed ID: 15644321 [TBL] [Abstract][Full Text] [Related]
31. Spatiotemporal control of interferon-induced JAK/STAT signalling and gene transcription by the retromer complex. Chmiest D; Sharma N; Zanin N; Viaris de Lesegno C; Shafaq-Zadah M; Sibut V; Dingli F; Hupé P; Wilmes S; Piehler J; Loew D; Johannes L; Schreiber G; Lamaze C Nat Commun; 2016 Dec; 7():13476. PubMed ID: 27917878 [TBL] [Abstract][Full Text] [Related]
32. BCR-ABL negative myeloproliferative neoplasia: a review of involved molecular mechanisms. Koopmans SM; Schouten HC; van Marion AM Histol Histopathol; 2015 Feb; 30(2):151-61. PubMed ID: 25196073 [TBL] [Abstract][Full Text] [Related]
33. Role of JAK-STAT signaling in the pathogenesis of myeloproliferative disorders. Levine RL; Wernig G Hematology Am Soc Hematol Educ Program; 2006; ():233-9, 510. PubMed ID: 17124066 [TBL] [Abstract][Full Text] [Related]
34. Distinct effects of ruxolitinib and interferon-alpha on murine JAK2V617F myeloproliferative neoplasm hematopoietic stem cell populations. Austin RJ; Straube J; Bruedigam C; Pali G; Jacquelin S; Vu T; Green J; Gräsel J; Lansink L; Cooper L; Lee SJ; Chen NT; Lee CW; Haque A; Heidel FH; D'Andrea R; Hill GR; Mullally A; Milsom MD; Bywater M; Lane SW Leukemia; 2020 Apr; 34(4):1075-1089. PubMed ID: 31732720 [TBL] [Abstract][Full Text] [Related]
35. MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia. Pikman Y; Lee BH; Mercher T; McDowell E; Ebert BL; Gozo M; Cuker A; Wernig G; Moore S; Galinsky I; DeAngelo DJ; Clark JJ; Lee SJ; Golub TR; Wadleigh M; Gilliland DG; Levine RL PLoS Med; 2006 Jul; 3(7):e270. PubMed ID: 16834459 [TBL] [Abstract][Full Text] [Related]